Hormonal
Tirzepatide treatment leads to significant weight loss in patients with hypothalamic obesity (HO) resulting from craniopharyngioma resection, despite the condition's historical resistance to standard therapies.
For patients with hypothalamic obesity due to brain tumors or surgery, standard diet and exercise often fail. Tirzepatide, a weekly injection starting at 2.5mg and increasing to 10mg, has shown significant weight loss in case reports. However, adherence is critical, as stopping the medication leads to rapid weight regain. Consult an endocrinologist to discuss if this treatment is appropriate for your specific condition.
This case report highlights the novel use of tirzepatide in the treatment of HO... The patient gradually lost 9 kg on tirzepatide, titrated from 2.5 mg to 10 mg over 4 months.
Why this rating
Single case report; lacks control group and long-term data; patient discontinued treatment.
Source
Successful Treatment of Hypothalamic Obesity with Tirzepatide
Sharmela Brijmohan et al. · AACE Endocrinology and Diabetes · 2025
DOI 10.1016/j.aed.2025.03.004
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →